BioSpace News Archive

Drug Development

Tocagen Plunges Following Phase III Flop of Brain Cancer Drug

Tocagen said the late-stage Toca 5 trial evaluating Toca 511 & Toca FC in patients with recurrent high-grade glioma undergoing resection missed its overall survival endpoint compared to standard of care treatment.

September 12, 2019
·
2 min read
·
Alex Keown
BioMidwest

Research Roundup: New Insights into Crohn’s Disease and More

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

September 12, 2019
·
5 min read
·
Mark Terry
Career Advice

Questions You Should Ask Yourself Before Accepting a Job Offer

You made it through the hardest parts of the job-seeking process — you crafted an excellent application, thoroughly researched the company and aced the interviews. Now you just need to decide whether to accept the offer extended to you.

September 12, 2019
·
3 min read
·
Laura Brothers
Are Drugmakers Going After the Right Targets in Cancer Cells?

Targeting plays a significantly important role in the fight against cancer, and many drugs that have been aimed at specific proteins in cancer cells may not work as initially designed. However, new research may provide a clue of where drug designers can look for potential cancer-killing solutions.

September 12, 2019
·
3 min read
·
Alex Keown
Bone Marrow Transplant Using CRISPR May Pave Way for HIV Cure

Chinese researchers published a study in the New England Journal of Medicine describing their use of a form of gene therapy to treat an HIV-positive man.

September 12, 2019
·
3 min read
·
Mark Terry
Policy

Follow the Money: How Biopharma Pays Off Congress

Kaiser Health News recently published “Pharma Cash To Congress,” a campaign contributions tracker. KHN noted that, “Members of Congress raked in almost $4 million from the pharmaceutical manufacturers and their trade groups in the first six months of 2019.

September 12, 2019
·
5 min read
·
Mark Terry
Advances in the Treatment of Chronic Asthma

A therapy that leads to fewer asthma attacks while reducing the need for corticosteroids is ideal, especially for those who continue to have severe symptoms while using traditional therapies. That’s where biologics come in.

September 12, 2019
·
5 min read
·
Gina Hagler
Business

Advanced Medical Solutions Group plc: Interim Results for the six months ended 30 June 2019

Advanced Medical Solutions Group plc announces its unaudited interim results for the six months ended 30 June 2019.

September 12, 2019
·
4 min read
Deals

Ermium Therapeutics completes Series A funding of €6.3 million to develop breakthrough auto-immune therapeutics

Ermium Therapeutics announced a series A funding of €6.3 M with Domain Therapeutics, Kurma Partners, Idinvest, and the SATT Erganeo.

September 12, 2019
·
4 min read
Deals

Primer Capital has invested in the development of a drug that eliminates the consequences of neurodegenerative diseases

The startup’s unique technology allows to halt the development of the short memory impairment that is characteristic of the patients with various neurodegenerative diseases.

September 12, 2019
·
2 min read